This is the question that's being asked, and we don't know that for a fact. What we do know is that what has been very important in the vaccines is the collaborative partnerships for scaling up production and technology transfer. What is of concern to some members is what a waiver might do to those collaborative relationships and whether it would actually be detrimental to vaccine production if you interfered with those relationships between the originators and the manufacturers.
It's not a given that the waiver is something that's worth trying because there are no negative consequences to the waiver. I'm not saying there are negative consequences. What I am saying is that we don't know, and there is a risk.